RU2010114024A - Применение гонадорелина в качестве терапевтического средства - Google Patents
Применение гонадорелина в качестве терапевтического средства Download PDFInfo
- Publication number
- RU2010114024A RU2010114024A RU2010114024/10A RU2010114024A RU2010114024A RU 2010114024 A RU2010114024 A RU 2010114024A RU 2010114024/10 A RU2010114024/10 A RU 2010114024/10A RU 2010114024 A RU2010114024 A RU 2010114024A RU 2010114024 A RU2010114024 A RU 2010114024A
- Authority
- RU
- Russia
- Prior art keywords
- gly
- diseases
- leu
- ser
- pharmaceutical composition
- Prior art date
Links
- 102400000932 Gonadoliberin-1 Human genes 0.000 title 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 title 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 title 1
- 229960001442 gonadorelin Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 10
- 208000035473 Communicable disease Diseases 0.000 claims abstract 9
- 239000000203 mixture Substances 0.000 claims abstract 7
- 239000007788 liquid Substances 0.000 claims abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 4
- 201000008827 tuberculosis Diseases 0.000 claims abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract 3
- 206010016654 Fibrosis Diseases 0.000 claims abstract 3
- 208000019693 Lung disease Diseases 0.000 claims abstract 3
- 201000011510 cancer Diseases 0.000 claims abstract 3
- 230000004761 fibrosis Effects 0.000 claims abstract 3
- 208000015181 infectious disease Diseases 0.000 claims abstract 3
- 208000027866 inflammatory disease Diseases 0.000 claims abstract 3
- 208000030159 metabolic disease Diseases 0.000 claims abstract 3
- 230000004770 neurodegeneration Effects 0.000 claims abstract 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 3
- 230000002265 prevention Effects 0.000 claims abstract 3
- GPXFZVUVPCFTMG-AVGNSLFASA-N Leu-Arg-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(C)C GPXFZVUVPCFTMG-AVGNSLFASA-N 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims abstract 2
- 210000000988 bone and bone Anatomy 0.000 claims abstract 2
- 239000000872 buffer Substances 0.000 claims abstract 2
- 239000007853 buffer solution Substances 0.000 claims abstract 2
- 210000003169 central nervous system Anatomy 0.000 claims abstract 2
- 239000002577 cryoprotective agent Substances 0.000 claims abstract 2
- 239000003085 diluting agent Substances 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims abstract 2
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 150000004677 hydrates Chemical class 0.000 claims abstract 2
- 238000001990 intravenous administration Methods 0.000 claims abstract 2
- 210000001503 joint Anatomy 0.000 claims abstract 2
- 210000004072 lung Anatomy 0.000 claims abstract 2
- 210000004324 lymphatic system Anatomy 0.000 claims abstract 2
- -1 lyoprotector Substances 0.000 claims abstract 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 210000003491 skin Anatomy 0.000 claims abstract 2
- 210000002229 urogenital system Anatomy 0.000 claims abstract 2
- 210000004251 human milk Anatomy 0.000 claims 2
- 235000020256 human milk Nutrition 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
Abstract
1. Сочетание пептидов Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 и Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH или их солей или гидратов. ! 2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%. ! 3. Сочетание по п.1 для применения в медицине. ! 4. Применение пептида Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ. ! 5. Применение пептида по п.4, где инфекционное заболевание выбрано из инфекции Mycobacterium tuberculosis и инфекционных заболеваний, вызванных инфекцией Mycobacterium tuberculosis, выбранных из инфекционных заболеваний легкого, центральной нервной системы, лимфатической системы, системы кровообращения, мочеполовой системы, костей, суставов и кожи. ! 6. Применение пептида Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста. ! 7. Применение пептида Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 для получения лиофилизированного состава или буферного жидкого состава. ! 8. Фармацевтическая композиция, содержащая сочетание по п.1 совместно с по меньшей мере одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем. ! 9. Фармацевтическая композиция по п.8 в форме лиофилизата или жидкого буферного раствора. ! 10. Фармацевтическая композиция по п.8 или 9, пригодная для внутривенного введения, перорального вве
Claims (12)
1. Сочетание пептидов Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 и Met-Gln-Met-Lys-Lys-Val-Leu-Asp-Ser-OH или их солей или гидратов.
2. Сочетание по п.1, где пептиды содержатся в сочетании в количестве от 30 мас.% к 70 мас.% до 70 мас.% к 30 мас.%.
3. Сочетание по п.1 для применения в медицине.
4. Применение пептида Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 или сочетания по п.1, или 2, или 3 для получения фармацевтической композиции для лечения и/или профилактики злокачественной опухоли, аутоиммунных заболеваний, фиброзов, воспалительных заболеваний, нейродегенеративных заболеваний, инфекционных заболеваний, заболеваний легких, заболеваний сердца и сосудов и болезней обмена веществ.
5. Применение пептида по п.4, где инфекционное заболевание выбрано из инфекции Mycobacterium tuberculosis и инфекционных заболеваний, вызванных инфекцией Mycobacterium tuberculosis, выбранных из инфекционных заболеваний легкого, центральной нервной системы, лимфатической системы, системы кровообращения, мочеполовой системы, костей, суставов и кожи.
6. Применение пептида Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 для получения состава для перорального введения новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
7. Применение пептида Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 для получения лиофилизированного состава или буферного жидкого состава.
8. Фармацевтическая композиция, содержащая сочетание по п.1 совместно с по меньшей мере одним фармацевтически приемлемым носителем, криопротектором, лиопротектором, эксципиентом и/или разбавителем.
9. Фармацевтическая композиция по п.8 в форме лиофилизата или жидкого буферного раствора.
10. Фармацевтическая композиция по п.8 или 9, пригодная для внутривенного введения, перорального введения или для введения посредством ингаляции.
11. Фармацевтическая композиция по п.8 или 9 в форме состава искусственного материнского молока или заменителя материнского молока, пригодная для пероральной доставки новорожденным, детям ясельного возраста и/или детям дошкольного возраста.
12. Фармацевтическая композиция по п.8 или 9, пригодная для лечения и/или профилактики злокачественной опухоли, аутоиммунного заболевания, фиброза, воспалительного заболевания, нейродегенеративного заболевания, инфекционного заболевания, заболевания легких, заболевания сердца и сосудов или болезни обмена веществ.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EPEP07017755.5 | 2007-09-11 | ||
EP07017755 | 2007-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2010114024A true RU2010114024A (ru) | 2011-10-20 |
Family
ID=40130545
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010114013/15A RU2010114013A (ru) | 2007-09-11 | 2008-09-09 | Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств |
RU2010113985/15A RU2010113985A (ru) | 2007-09-11 | 2008-09-09 | Применение уродилатина в качестве терапевтического средства |
RU2010114056/15A RU2010114056A (ru) | 2007-09-11 | 2008-09-09 | Терапевтическое применение пептидов интермедина 47 и 53 |
RU2010114043/15A RU2010114043A (ru) | 2007-09-11 | 2008-09-09 | Применение бета-меланотропина в качестве терапевтического средства, например, для лечения спид или болезни альцгеймера |
RU2010114057/15A RU2010114057A (ru) | 2007-09-11 | 2008-09-09 | Применение натрийуретического пептида с-типа индивидуально или в сочетании с нейропептидом af в качестве терапевтического средства |
RU2010113972/15A RU2010113972A (ru) | 2007-09-11 | 2008-09-09 | Применение cnp-22 отдельно или в сочетании с физалемином в качестве терапевтического средства |
RU2010114024/10A RU2010114024A (ru) | 2007-09-11 | 2008-09-09 | Применение гонадорелина в качестве терапевтического средства |
RU2010114004/15A RU2010114004A (ru) | 2007-09-11 | 2008-09-09 | Применение меланиноконцентрирующего гормона и met-энкефалина в качестве терапевтических средств |
Family Applications Before (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010114013/15A RU2010114013A (ru) | 2007-09-11 | 2008-09-09 | Применение нейротрофического фактора для холинергических нейронов сетчатки (nfrcn) и хорионического гонадотропина бета (109-145) в качестве терапевтических средств |
RU2010113985/15A RU2010113985A (ru) | 2007-09-11 | 2008-09-09 | Применение уродилатина в качестве терапевтического средства |
RU2010114056/15A RU2010114056A (ru) | 2007-09-11 | 2008-09-09 | Терапевтическое применение пептидов интермедина 47 и 53 |
RU2010114043/15A RU2010114043A (ru) | 2007-09-11 | 2008-09-09 | Применение бета-меланотропина в качестве терапевтического средства, например, для лечения спид или болезни альцгеймера |
RU2010114057/15A RU2010114057A (ru) | 2007-09-11 | 2008-09-09 | Применение натрийуретического пептида с-типа индивидуально или в сочетании с нейропептидом af в качестве терапевтического средства |
RU2010113972/15A RU2010113972A (ru) | 2007-09-11 | 2008-09-09 | Применение cnp-22 отдельно или в сочетании с физалемином в качестве терапевтического средства |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2010114004/15A RU2010114004A (ru) | 2007-09-11 | 2008-09-09 | Применение меланиноконцентрирующего гормона и met-энкефалина в качестве терапевтических средств |
Country Status (8)
Country | Link |
---|---|
US (9) | US20100210538A1 (ru) |
EP (9) | EP2187944A1 (ru) |
JP (8) | JP2010539051A (ru) |
KR (8) | KR20100056510A (ru) |
AU (8) | AU2008297898A1 (ru) |
CA (8) | CA2699104A1 (ru) |
RU (8) | RU2010114013A (ru) |
WO (21) | WO2009033724A1 (ru) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE039448T2 (hu) | 2004-04-21 | 2018-12-28 | Alexion Pharma Inc | Csontba szállító konjugátumok és alkalmazási módszerük a fehérjék csontba juttatására |
PT1865976E (pt) | 2005-04-07 | 2012-08-03 | Cardiopep Pharma Gmbh | Utilização de péptido natriurético para tratar a insuficiência cardíaca |
JP4593639B2 (ja) | 2008-03-04 | 2010-12-08 | 株式会社マルハニチロ食品 | ペプチド含有摂食調節剤 |
PE20120792A1 (es) | 2009-05-20 | 2012-07-27 | Biomarin Pharm Inc | Variantes de peptidos natriureticos de tipo c |
RU2572694C2 (ru) * | 2009-07-23 | 2016-01-20 | ИГИСУ Ко., Лтд. | Композиция кожного препарата для наружного применения |
BR112012004058A2 (pt) * | 2009-08-27 | 2021-08-17 | Kyoko Endo | preparação terapêutica para rinite |
WO2011153531A1 (en) | 2010-06-04 | 2011-12-08 | University Of South Florida | Method of treating skeletal dysplasias using vessel dilator |
WO2012016229A2 (en) * | 2010-07-30 | 2012-02-02 | The Regents Of The University Of California | Oxytocin treatment to improve memory and modify blood glucose |
EP2658979B1 (en) | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
ES2647680T3 (es) * | 2011-01-21 | 2017-12-26 | Igisu Co., Ltd. | Fármaco terapéutico para la alopecia |
US20120277155A1 (en) | 2011-02-25 | 2012-11-01 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
JP5948683B2 (ja) * | 2011-02-28 | 2016-07-06 | 国立研究開発法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
CN103764165A (zh) * | 2011-08-19 | 2014-04-30 | 独立行政法人国立循环器病研究中心 | 组合利尿钠肽受体gc-a激动剂以及gc-b激动剂而成的用于防止恶性肿瘤恶化的药品 |
EP2750697A4 (en) | 2011-09-02 | 2015-03-25 | Medtronic Inc | CHIMERIC NATRIURETIC PEPTIDE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF |
CN102380089A (zh) * | 2011-11-14 | 2012-03-21 | 北京大学 | 中介素1-53在制备糖代谢紊乱治疗药物中的新用途 |
CN102389567A (zh) * | 2011-11-14 | 2012-03-28 | 北京大学 | 中介素1-53在制备脂代谢紊乱治疗药物中的新用途 |
CN102441159B (zh) * | 2011-12-08 | 2013-12-25 | 赵海潞 | 一种人类多肽在制备免疫调节剂中的应用 |
EP2790714A4 (en) * | 2011-12-16 | 2015-08-05 | Kalos Therapeutics Inc | METHODS AND USES OF PEPTIDES SSOCIATED TO ANP (ATRIAL NATRIURETIC PEPTIDE), BNP (NATRIURETIC BRAIN PEPTIDE), AND CNP (NATRIURETIC PEPTIDE TYPE C) AND DERIVATIVES THEREOF FOR THE TREATMENT OF RETINO DISORDERS AND DISEASES |
ES2425448B8 (es) * | 2012-03-12 | 2015-03-17 | Universidade De Santiago De Compostela | Uso de la obestatina para la regeneración muscular |
RU2496504C1 (ru) * | 2012-03-22 | 2013-10-27 | Федеральное государственное бюджетное учреждение "Научный центр биомедицинских технологий" Российской академии медицинских наук | Средство для стимуляции работы в экстремальных условиях, способ его получения и его применения |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2014116786A1 (en) * | 2013-01-25 | 2014-07-31 | Zietchick Research Institute,Llc | Use of human chorionic gonadotropin to treat cerebral palsy and/or its co-morbidities |
RU2521197C1 (ru) * | 2013-03-22 | 2014-06-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РостГМУ Минздрава России) | Способ лечения больных деструктивными формами туберкулеза легких |
JP2017518373A (ja) * | 2014-05-29 | 2017-07-06 | グリーン・クロス・コーポレイションGreen Cross Corp. | スタフィロコッカス・アウレウス感染疾患の予防または治療用組成物 |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
HRP20240166T1 (hr) | 2014-09-19 | 2024-04-26 | Ferring B.V. | Postupak liječenja prader-willijevog sindroma |
MX2017005692A (es) | 2014-10-31 | 2017-08-07 | Glaxosmithkline Ip Dev Ltd | Formulacion en polvo. |
JP6787894B2 (ja) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 組換えアルカリホスファターゼを用いた発作の処置 |
AU2016211447B2 (en) | 2015-01-28 | 2021-09-23 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
US20180169139A1 (en) * | 2015-06-10 | 2018-06-21 | Cellphire, Inc. | Composition and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia |
RU2587332C1 (ru) * | 2015-07-01 | 2016-06-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО РостГМУ Минздрава России) | Способ лечения больных деструктивными формами туберкулеза легких |
WO2017010845A1 (ko) * | 2015-07-15 | 2017-01-19 | 재단법인 목암생명과학연구소 | 포도상구균 감염 질환의 예방 또는 치료용 조성물 |
KR102644116B1 (ko) | 2015-08-17 | 2024-03-05 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼린 포스파타제의 제조 |
KR101727397B1 (ko) | 2015-09-15 | 2017-04-17 | 경희대학교 산학협력단 | 멜라닌 응집 호르몬을 유효성분으로 포함하는 통증 억제용 조성물 |
EP3355904A4 (en) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA |
WO2017064302A1 (en) * | 2015-10-16 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases |
EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING CRANIOSYNOSTOSIS IN A PATIENT |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | METHODS OF TREATING HYPOPHOSPHATASE IN CHILDREN |
MX2018011833A (es) | 2016-04-01 | 2019-02-13 | Alexion Pharma Inc | Tratamiento para la debilidad muscular con fosfatasas alcalinas. |
EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
WO2018134373A1 (en) | 2017-01-20 | 2018-07-26 | Immune System Regulation Holding Ab | Novel compounds (immunorhelins- intracellular infections) |
US11304990B2 (en) * | 2017-01-20 | 2022-04-19 | ISR Immune System Regulation Holding AB (publ) | Use of known compounds—intracellular infections |
EP3571213A1 (en) | 2017-01-20 | 2019-11-27 | Immune System Regulation Holding AB | Novel compounds (immunorhelins) |
JP2020508306A (ja) | 2017-02-22 | 2020-03-19 | イミューン システム レギュレェイション ホールディング エービー | アジュバント免疫療法剤として使用するためのゴナドトロピン放出ホルモン |
AU2018243320A1 (en) | 2017-03-31 | 2019-10-10 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
CN108186583A (zh) * | 2018-03-28 | 2018-06-22 | 宁波第二激素厂 | 一种兽用戈那瑞林注射剂的制备方法 |
WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
EP3852724A4 (en) | 2018-09-20 | 2022-07-06 | Levo Therapeutics, Inc. | CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE |
TW202031283A (zh) | 2018-09-20 | 2020-09-01 | 馬克 C 曼寧 | 穩定卡貝縮宮素鼻內製劑 |
EP3886879A4 (en) | 2018-11-30 | 2022-12-07 | Cellphire Inc. | PLATES AS DELIVERY AGENTS |
EP3887404A4 (en) | 2018-11-30 | 2022-11-02 | Cellphire, Inc. | SLIDES LOADED WITH ANTI-CANCER AGENTS |
CN109893646A (zh) * | 2019-03-19 | 2019-06-18 | 南京星银药业集团有限公司 | 一种治疗抑郁症的组合物 |
SG11202112054WA (en) | 2019-05-03 | 2021-11-29 | Cellphire Inc | Materials and methods for producing blood products |
FR3099056B1 (fr) * | 2019-07-26 | 2022-08-12 | Univ Rouen Normandie | Utilisation de l’ANP pour détruire les biofilms bactériens |
BR112022002892A2 (pt) | 2019-08-16 | 2022-05-24 | Cellphire Inc | Trombossomos como um agente de reversão de agente antiplaqueta |
CN112641928A (zh) * | 2019-10-11 | 2021-04-13 | 田中纯美 | 一种用于血管新生、淋巴管新生相关疾病的多肽及其用途 |
WO2021158622A1 (en) | 2020-02-04 | 2021-08-12 | Cellphire, Inc. | Anti-fibrinolytic loaded platelets |
US11419917B2 (en) | 2020-04-07 | 2022-08-23 | Drora Shevy | Treatment for SARS-CoV-2 and other coronaviruses |
WO2022029499A1 (en) * | 2020-08-06 | 2022-02-10 | Ads Aiphia Development Services Ag | Methods of treating refractory ascites |
CN112212178B (zh) * | 2020-09-11 | 2022-04-01 | 山东中科诺亚科技有限公司 | 一种基于自转向的森林火灾监控装置 |
CN114940990B (zh) * | 2022-06-20 | 2023-03-14 | 北京市神经外科研究所 | 与颅内动脉瘤相关的基因突变位点及其应用 |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4188373A (en) | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4100271A (en) | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4235988A (en) | 1976-12-13 | 1980-11-25 | Imperial Chemical Industries Limited | Delivery means for biologically active agents |
US4321260A (en) * | 1980-05-22 | 1982-03-23 | Ayerst, Mckenna & Harrison Inc. | Method of using gonadorelin for the treatment of benign prostatic hyperplasia |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474753A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4474751A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Ophthalmic drug delivery system utilizing thermosetting gels |
US4496521A (en) * | 1983-07-15 | 1985-01-29 | The Whittier Institute For Diabetes And Endocrinology | Insulin-potentiating peptides |
US5432176A (en) * | 1988-11-29 | 1995-07-11 | The John Hopkins University | Method of retarding the progression of chronic renal failure |
US5324510A (en) * | 1989-09-01 | 1994-06-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | Use of antibodies to intercellular adhesion molecule-1 (ICAM-1) in the treatment of asthma |
US5262520A (en) * | 1989-12-01 | 1993-11-16 | The Scripps Research Institute | Peptides and antibodies that inhibit integrin-ligand binding |
WO1991018010A1 (en) * | 1990-05-15 | 1991-11-28 | Swinburne Limited | Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof |
JP2977159B2 (ja) * | 1990-09-07 | 1999-11-10 | 壽之 松尾 | カエル由来新規生理活性ペプチド(カエルcnp) |
JP3130080B2 (ja) * | 1990-12-27 | 2001-01-31 | 日清製粉株式会社 | ペプチドおよびその製造方法 |
US5256766A (en) * | 1991-02-19 | 1993-10-26 | The Regents Of The University Of California | Recombinant thrombin receptor and related pharmaceuticals |
EP0668770A1 (en) * | 1991-04-24 | 1995-08-30 | Warner-Lambert Company | $g(a)-SUBSTITUTED POLYPEPTIDES HAVING THERAPEUTIC ACTIVITY |
ATE160486T1 (de) | 1991-08-12 | 1997-12-15 | Nestle Sa | Nahrungsmittelzusammensetzung |
IL106998A0 (en) * | 1992-09-17 | 1993-12-28 | Univ Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
DE4310632A1 (de) * | 1993-04-01 | 1994-10-06 | Merck Patent Gmbh | Lineare Adhäsionsinhibitoren |
KR100232297B1 (ko) | 1994-05-06 | 1999-12-01 | 디. 제이. 우드 | 아지트로마이신의 제어된 방출 투여형 제제 |
WO1995030418A1 (en) * | 1994-05-09 | 1995-11-16 | The Johns Hopkins University | Method of slowing the progression of hiv infection |
US5677275A (en) * | 1994-08-05 | 1997-10-14 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of cancer with human chorionic gonadotropin |
US5849708A (en) * | 1995-06-06 | 1998-12-15 | Joslin Diabetes Center, Inc. | Promotion of eating behavior |
EP0885016B1 (en) | 1996-02-19 | 2003-04-16 | Amersham Health AS | Thermally stabilized contrast agent |
JPH09227590A (ja) * | 1996-02-27 | 1997-09-02 | Nisshin Flour Milling Co Ltd | ペプチド |
EP0885010B1 (en) * | 1996-03-06 | 2003-06-04 | Boehringer Ingelheim Pharmaceuticals Inc. | Intercellular adhesion molecule powder formulation |
US6136780A (en) * | 1996-03-29 | 2000-10-24 | The Penn State Research Foundation | Control of cancer growth through the interaction of [Met5 ]-enkephalin and the zeta (ζ) receptor |
US20040063790A1 (en) * | 1996-05-31 | 2004-04-01 | The Scripps Research Institute | Methods for inhibition of angiogenesis |
AU3587797A (en) * | 1996-06-24 | 1998-01-14 | University Of Maryland Biotechnology Institute | Methods of treatment of wasting syndrome based on administration of derivatives of human chorionic gonadotropin |
TW360501B (en) | 1996-06-27 | 1999-06-11 | Nestle Sa | Dietetically balanced milk product |
GB9613705D0 (en) * | 1996-06-29 | 1996-08-28 | Mini Agriculture & Fisheries | Novel peptides |
DK0832565T3 (da) | 1996-09-24 | 2000-11-20 | Nestle Sa | Mælkeerstatningsprodukt og fremgangsmåde til fremstilling deraf |
SE9701162D0 (sv) * | 1997-03-27 | 1997-03-27 | Karolinska Innovations Ab | New use II |
US6583109B1 (en) * | 1997-06-24 | 2003-06-24 | Robert C. Gallo | Therapeutic polypeptides from β-hCG and derivatives |
IL123349A0 (en) * | 1998-02-18 | 1998-09-24 | Hadasit Med Res Service | Agents for the prevention of damages caused by stress conditions |
US7175679B2 (en) * | 2001-03-29 | 2007-02-13 | Biotempt B.V. | Oligopeptide treatment of NF-κB mediated inflammation |
GB9816234D0 (en) * | 1998-07-24 | 1998-09-23 | William Harvey Research Limite | Compounds for use in the treatment of inflammation |
US6333313B1 (en) * | 1998-10-29 | 2001-12-25 | Board Of Regents, The University Of Texas System | Clinical use of oxytocin alone or in combination to treat bone disorders |
BR9915573B1 (pt) | 1998-11-24 | 2010-11-30 | processo de preparação de uma formulação infantil predominantemente a base de uma matéria-prima de leite oriunda de soro do leite, em que a composição em aminoácidos é semelhante àquela do leite humano. | |
AU776795B2 (en) * | 1998-12-18 | 2004-09-23 | Avi Biopharma, Inc. | Chorionic gonadotropin DNA vaccines and methods |
DE19903087A1 (de) * | 1999-01-27 | 2000-08-10 | Forssmann Wolf Georg | Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern |
US20040259803A1 (en) * | 1999-04-15 | 2004-12-23 | Monash University | Disease prevention by reactivation of the thymus |
US20040013641A1 (en) * | 1999-04-15 | 2004-01-22 | Monash University | Disease prevention by reactivation of the thymus |
EP1173195B1 (en) * | 1999-04-21 | 2007-10-10 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
WO2000069900A2 (en) * | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
DE19942230C2 (de) * | 1999-09-03 | 2003-09-25 | Wolf-Georg Forssmann | Verwendung natriuretischer Peptide als antibiotisch wirksame Subsanzen zur Behandlung von bakteriellen Infektionen |
WO2001017958A2 (en) * | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Neuropeptide sf receptor assays, compounds and therapeutic methods |
CA2395714A1 (en) * | 1999-12-21 | 2001-06-28 | Takeda Chemical Industries, Ltd. | Novel tachykinin-like polypeptides and use thereof |
US6894026B1 (en) * | 2000-01-11 | 2005-05-17 | Atossa Healthcare, Inc. | Long-acting oxytocin analogues for the treatment and prevention of breast cancer and psychiatric disorders |
US20010046968A1 (en) * | 2000-03-23 | 2001-11-29 | Zagon Ian S. | Opioid growth factor modulates angiogenesis |
JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
SE0001440D0 (sv) * | 2000-04-18 | 2000-04-18 | Entretech Medical Ab | A drug against climacteric disorders |
ATE282426T1 (de) * | 2001-02-24 | 2004-12-15 | Mologen Ag | Beta-endorphin / crf - gentherapie zur lokalen schmerzbekämpfung |
SE0100684D0 (sv) * | 2001-02-28 | 2001-02-28 | Kerstin Uvnaes Moberg | New subject-matter |
WO2002085401A1 (en) * | 2001-04-18 | 2002-10-31 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
KR100411828B1 (ko) * | 2001-04-21 | 2003-12-24 | 김수열 | 항 염증 효과가 있는 새로운 합성 펩타이드 |
WO2002092018A2 (en) * | 2001-05-16 | 2002-11-21 | Plotnikoff Nicholas P | Methods for inducing sustained immune response |
GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
SE0102910D0 (sv) * | 2001-08-31 | 2001-08-31 | Moberg Kerstin Uvnaes | New use |
US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
ES2287065T3 (es) | 2001-11-23 | 2007-12-16 | Societe Des Produits Nestle S.A. | Proceso para la preparacion de leche en polvo y productos lacteos concentrados. |
US7101845B2 (en) * | 2002-01-31 | 2006-09-05 | Joslin Diabetes Center, Inc. | Methods of modulating β cell function |
DE10209072A1 (de) * | 2002-02-28 | 2003-09-18 | Universitaetsklinikum Charite | Mittel zur Reduktion des Körpergewichts |
AU2003218213A1 (en) * | 2002-03-18 | 2003-10-08 | Beth Israel Deaconess Medical Center | Protease activity of thrombin inhibits angiogenesis |
CA2391118A1 (en) * | 2002-06-21 | 2003-12-21 | Universite Du Quebec A Montreal | Oxytocin as cardiomyogenesis inducer and uses thereof |
JP4249970B2 (ja) * | 2002-10-17 | 2009-04-08 | 扶桑薬品工業株式会社 | Par−1を介する消化器系疾患の予防および/または治療用組成物 |
WO2004037168A2 (en) * | 2002-10-18 | 2004-05-06 | Amylin Pharmaceuticals, Inc. | Treatment of pancreatitis with amylin |
US6969702B2 (en) * | 2002-11-20 | 2005-11-29 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
JP5420813B2 (ja) * | 2002-11-20 | 2014-02-19 | ニューロノバ エービー | 神経発生を増大させるための組成物および方法 |
AU2003298739A1 (en) * | 2002-11-26 | 2004-06-18 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
WO2004069175A2 (en) * | 2003-02-02 | 2004-08-19 | Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES |
GB0323378D0 (en) * | 2003-10-07 | 2003-11-05 | Univ Leicester | Therapeutic agent |
EP1522856A1 (en) * | 2003-10-09 | 2005-04-13 | BioVisioN AG | Method for the detection of a neurological or psychiatric, demential disease, especially Alzheimer's disease by use of cholecystokinin (CCK)-molecules, corresponding substances and detection reagents |
US20070053954A1 (en) * | 2003-10-24 | 2007-03-08 | Rowe Stephen C | Macromer-melt formulations |
EP1529535A1 (en) * | 2003-11-06 | 2005-05-11 | IPF PharmaCeuticals GmbH | Isolation of a circulating human lipolytic peptide |
US20050143303A1 (en) * | 2003-12-26 | 2005-06-30 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
US8076288B2 (en) * | 2004-02-11 | 2011-12-13 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides having glucose lowering activity |
WO2005082397A1 (en) * | 2004-02-26 | 2005-09-09 | The Penn State Research Foundation | Combinatorial therapies for the treatment of neoplasias using the opioid growth factor receptor |
US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
EP3446711A1 (en) * | 2004-03-31 | 2019-02-27 | Kazuwa Nakao | Composition for increasing body height |
WO2005094889A1 (ja) * | 2004-03-31 | 2005-10-13 | Chugai Seiyaku Kabushiki Kaisha | 関節炎症治療剤又は予防剤 |
BRPI0516574A (pt) * | 2004-10-08 | 2008-09-16 | Amylin Pharmaceuticals Inc | análogos do polipeptìdeo-6 da famìlia amilina (afp-6) e métodos para preparar e usar os mesmos |
WO2006060873A1 (en) * | 2004-12-09 | 2006-06-15 | Prince Henry's Institute Of Medical Research | Method for restoring reproductive function |
EP1829969B1 (en) * | 2004-12-24 | 2012-11-28 | National Cerebral and Cardiovascular Center | Novel polypeptide and the use thereof |
US20060177438A1 (en) * | 2005-02-08 | 2006-08-10 | New England Medical Center | Methods of altering absorption of hydrophobic compounds |
AU2006211996A1 (en) * | 2005-02-09 | 2006-08-17 | Centre National De La Recherche Scientifique | Colonic delivery of active agents |
WO2006086769A2 (en) * | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Inc. | Gip analog and hybrid polypeptides with selectable properties |
WO2007022123A2 (en) * | 2005-08-11 | 2007-02-22 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP1861416A1 (en) * | 2005-03-09 | 2007-12-05 | The Board of Trustees of Leland Stanford Junior University | Obestatin and its uses |
US20060281670A1 (en) * | 2005-06-10 | 2006-12-14 | Wisconsin Alumni Research Foundation (Warf) | Compositions and methods for modulating angiogenesis |
WO2007014051A2 (en) * | 2005-07-22 | 2007-02-01 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
GB0516091D0 (en) * | 2005-08-04 | 2005-09-14 | Haemostatix Ltd | Therapeutic agent |
JP2009506773A (ja) * | 2005-09-01 | 2009-02-19 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | メラノサイト刺激ホルモンペプチド模倣体 |
US20090035287A1 (en) * | 2005-09-26 | 2009-02-05 | Zurit Levine | Atrial natriuretic peptide (anp) splice variants and methods of using same |
WO2007044998A1 (en) * | 2005-10-12 | 2007-04-19 | The Regents Of The University Of California | Retrocyclins: antiviral and antimicrobial peptides |
WO2007055743A2 (en) * | 2005-11-01 | 2007-05-18 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
JP2009519949A (ja) * | 2005-12-16 | 2009-05-21 | アミリン・ファーマシューティカルズ,インコーポレイテッド | 肥満症および関連する代謝性疾患の治療のための組成物および方法 |
AU2007209725A1 (en) * | 2006-01-24 | 2007-08-02 | Sirius Genomics Inc. | Vasopressin pathway polymorphisms as indicators of subject outcome in critically ill subjects |
BRPI0708773B1 (pt) | 2006-03-10 | 2021-10-19 | Laboswiss Ag | Método para solubilização, dispersão e estabilização de substâncias, produtos manufaturados de acordo com o método, bem como uso dos mesmos |
ATE516300T1 (de) * | 2006-03-20 | 2011-07-15 | Merck Sharp & Dohme | Neuromedin-u-rezeptoragonisten und ihre verwendung |
KR20080106950A (ko) * | 2006-03-31 | 2008-12-09 | 아밀린 파마슈티칼스, 인크. | 정신의학적 질환 및 장애를 치료하기 위한 아밀린 및 아밀린 효능제 |
JP2009536670A (ja) * | 2006-05-10 | 2009-10-15 | スミスクライン・ビーチャム・コーポレイション | 化合物の細胞浸透性を増加させるための組成物および方法 |
EP2052739A4 (en) * | 2006-08-16 | 2010-01-06 | Forerunner Pharma Res Co Ltd | MEDICINE FOR THE TREATMENT OF CANCER WITH A LIGAND FOR NEUROMEDIN U-RECEPTOR 2 (FM4) MOLECULE AS AN ACTIVE SUBSTANCE |
EP2081557A1 (en) * | 2006-11-17 | 2009-07-29 | DA Volterra | Colonic delivery using zn/pectin beads with a eudragit coating. |
ES2389747T3 (es) * | 2007-02-05 | 2012-10-31 | Amylin Pharmaceuticals, Inc. | Péptidos FN-38 para su uso en el tratamiento de desórdenes psicóticos y de ansiedad |
EP2146733B1 (en) * | 2007-03-14 | 2020-11-25 | Arch Biosurgery, Inc. | Treatment of leaky or damaged tight junctions and enhancing extracellular matrix |
US20110301079A1 (en) * | 2007-09-21 | 2011-12-08 | Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Neuromedin u receptor agonists and uses thereof |
-
2008
- 2008-09-09 WO PCT/EP2008/007651 patent/WO2009033724A1/en active Application Filing
- 2008-09-09 CA CA2699104A patent/CA2699104A1/en not_active Abandoned
- 2008-09-09 EP EP08830714A patent/EP2187944A1/en not_active Withdrawn
- 2008-09-09 RU RU2010114013/15A patent/RU2010114013A/ru not_active Application Discontinuation
- 2008-09-09 KR KR1020107005597A patent/KR20100056510A/ko not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007621 patent/WO2009043450A2/en active Application Filing
- 2008-09-09 EP EP08785866A patent/EP2185171A2/en not_active Withdrawn
- 2008-09-09 JP JP2010523424A patent/JP2010539051A/ja active Pending
- 2008-09-09 WO PCT/EP2008/007564 patent/WO2009033707A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007936 patent/WO2009046852A1/en active Application Filing
- 2008-09-09 EP EP08802517A patent/EP2190459A1/en not_active Withdrawn
- 2008-09-09 EP EP08802142A patent/EP2187921A2/en not_active Withdrawn
- 2008-09-09 US US12/677,731 patent/US20100210538A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/008036 patent/WO2009043505A2/en active Application Filing
- 2008-09-09 CA CA2698828A patent/CA2698828A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005616A patent/KR20100058554A/ko not_active Application Discontinuation
- 2008-09-09 US US12/677,459 patent/US20100190717A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007543 patent/WO2009033701A1/en active Application Filing
- 2008-09-09 AU AU2008297898A patent/AU2008297898A1/en not_active Abandoned
- 2008-09-09 CA CA2698977A patent/CA2698977A1/en not_active Abandoned
- 2008-09-09 CA CA2698971A patent/CA2698971A1/en not_active Abandoned
- 2008-09-09 RU RU2010113985/15A patent/RU2010113985A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08802195A patent/EP2185177A1/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007995 patent/WO2009033795A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007714 patent/WO2009040020A1/en active Application Filing
- 2008-09-09 KR KR1020107005661A patent/KR20100059865A/ko not_active Application Discontinuation
- 2008-09-09 KR KR1020107005634A patent/KR20100057057A/ko not_active Application Discontinuation
- 2008-09-09 JP JP2010523395A patent/JP2010539022A/ja active Pending
- 2008-09-09 US US12/677,547 patent/US20100204090A1/en not_active Abandoned
- 2008-09-09 AU AU2008306255A patent/AU2008306255A1/en not_active Abandoned
- 2008-09-09 AU AU2008297875A patent/AU2008297875A1/en not_active Abandoned
- 2008-09-09 US US12/677,304 patent/US20100204109A1/en not_active Abandoned
- 2008-09-09 US US12/677,105 patent/US20100204107A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007638 patent/WO2009043458A2/en active Application Filing
- 2008-09-09 JP JP2010523375A patent/JP2010539002A/ja active Pending
- 2008-09-09 AU AU2008306217A patent/AU2008306217A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/007927 patent/WO2009046844A1/en active Application Filing
- 2008-09-09 EP EP08802526A patent/EP2190456A2/en not_active Withdrawn
- 2008-09-09 AU AU2008310078A patent/AU2008310078A1/en not_active Abandoned
- 2008-09-09 JP JP2010523429A patent/JP2010539056A/ja active Pending
- 2008-09-09 EP EP08802440A patent/EP2205269A1/en not_active Withdrawn
- 2008-09-09 RU RU2010114056/15A patent/RU2010114056A/ru not_active Application Discontinuation
- 2008-09-09 CA CA2698778A patent/CA2698778A1/en not_active Abandoned
- 2008-09-09 WO PCT/EP2008/008110 patent/WO2009043527A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/008027 patent/WO2009046861A1/en active Application Filing
- 2008-09-09 JP JP2010523389A patent/JP2010539016A/ja active Pending
- 2008-09-09 WO PCT/EP2008/008031 patent/WO2009046865A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007538 patent/WO2009039990A2/en active Application Filing
- 2008-09-09 US US12/677,300 patent/US20100204108A1/en not_active Abandoned
- 2008-09-09 AU AU2008309993A patent/AU2008309993A1/en not_active Abandoned
- 2008-09-09 US US12/677,780 patent/US20100323950A1/en not_active Abandoned
- 2008-09-09 JP JP2010523432A patent/JP2010539059A/ja active Pending
- 2008-09-09 RU RU2010114043/15A patent/RU2010114043A/ru not_active Application Discontinuation
- 2008-09-09 CA CA2698687A patent/CA2698687A1/en not_active Abandoned
- 2008-09-09 CA CA2699084A patent/CA2699084A1/en not_active Abandoned
- 2008-09-09 RU RU2010114057/15A patent/RU2010114057A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007619 patent/WO2009043448A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007591 patent/WO2009033717A2/en active Application Filing
- 2008-09-09 RU RU2010113972/15A patent/RU2010113972A/ru not_active Application Discontinuation
- 2008-09-09 WO PCT/EP2008/007606 patent/WO2009043439A2/en active Application Filing
- 2008-09-09 US US12/677,108 patent/US8349805B2/en not_active Expired - Fee Related
- 2008-09-09 KR KR1020107005620A patent/KR20100059859A/ko not_active Application Discontinuation
- 2008-09-09 JP JP2010523401A patent/JP2010539028A/ja active Pending
- 2008-09-09 KR KR1020107005600A patent/KR20100057049A/ko not_active Application Discontinuation
- 2008-09-09 US US12/677,735 patent/US20100249017A1/en not_active Abandoned
- 2008-09-09 RU RU2010114024/10A patent/RU2010114024A/ru not_active Application Discontinuation
- 2008-09-09 CA CA2699169A patent/CA2699169A1/en not_active Abandoned
- 2008-09-09 KR KR1020107005653A patent/KR20100057641A/ko not_active Application Discontinuation
- 2008-09-09 EP EP08802117A patent/EP2197466A2/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007673 patent/WO2009033735A2/en active Application Filing
- 2008-09-09 KR KR1020107005654A patent/KR20100057642A/ko not_active Application Discontinuation
- 2008-09-09 AU AU2008297909A patent/AU2008297909A1/en not_active Abandoned
- 2008-09-09 RU RU2010114004/15A patent/RU2010114004A/ru not_active Application Discontinuation
- 2008-09-09 EP EP08830541A patent/EP2190450A2/en not_active Withdrawn
- 2008-09-09 WO PCT/EP2008/007719 patent/WO2009033744A1/en active Application Filing
- 2008-09-09 AU AU2008297891A patent/AU2008297891A1/en not_active Abandoned
- 2008-09-09 JP JP2010523381A patent/JP5385279B2/ja not_active Expired - Fee Related
- 2008-09-09 WO PCT/EP2008/007637 patent/WO2009043457A2/en active Application Filing
- 2008-09-09 WO PCT/EP2008/007646 patent/WO2009043466A2/en active Application Filing
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010114024A (ru) | Применение гонадорелина в качестве терапевтического средства | |
RU2010114040A (ru) | Применение дезлорелина и мастопана в качестве терапевтического средства | |
RU2010114031A (ru) | Проадреномедуллин индивидуально или в сочетании с большим гастрином i в качестве терапевтического средства | |
RU2010113986A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114027A (ru) | Большой гастрин i в качестве терапевтического средства | |
RU2010114042A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010113989A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010113998A (ru) | Применение пептида rfmwmr в качестве терапевтического средства | |
RU2010114044A (ru) | Применение белка полосы 3 (824-829) и/или фактора ингибирования высвобождения меланотропина в качестве терапевтического средства при лечении инфекции pseudomonas aeruginosa | |
RU2010114014A (ru) | Применение глюкагона (1-29) отдельно или в сочетании с нейропептидом w30 в качестве терапевтического средства | |
RU2010114045A (ru) | Применение пептида sfllr-oh и мурамилдипептида в качестве терапевтических средств | |
RU2010114033A (ru) | Применение ингибитора nf-каппа в sn50 и необязательно ангиотензина iii в качестве терапевтических средств при лечении, например, инфекции hbv | |
RU2010114030A (ru) | Применение пептида в качестве терапевтического средства | |
RU2010114032A (ru) | Применение салусина бета индивидуально или в комбинации с октреотидом в качестве терапевтического средства | |
RU2010114051A (ru) | Применение grf-1(1-29) и кортиколиберина в качестве терапевтических средств | |
RU2010114049A (ru) | Cgrp в качестве терапевтического средства | |
RU2010114039A (ru) | Применение октреотида в качестве терапевтического средства | |
RU2010114035A (ru) | Применение rfrp индивидуально или в комбинации с нейрокинином в в качестве терапевтического средства | |
RU2010114005A (ru) | Применение сочетания пептидов тимозина бета4 и индуцирующего дельта-сон пептида в качестве терапевтического средства | |
RU2010114037A (ru) | Применение белка полосы 3 и расар-27 в качестве терапевтического средства | |
RU2010114060A (ru) | Применение пептида в качестве терапевтического средства |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20111012 |